匹伐他汀钙与阿托伐他汀钙治疗冠心病的临床疗效及安全性比较.

To comparison the efficacy and safety of pivastatin calcium and atorvastatin calcium in the Treatment of Coronary Heart Disease. 100 patients with coronary heart disease from March 2016 to December 2018 were divided into the pitavastatin calcium group(n=50) and the atorvastatin calcium group (n=50). The blood glucose(Glu), Glycated hemoglobin(HbA1c), Ultra- sensitive C reaction protein (hsCRP), Total cholesterol (TC), Triglycerides (TG), Low density lipoprotein cholesterol (LDL-C), High-density lipoprotein cholesterol(HDL-C), Acetyltransferase(ALT), Valley grass transaminase(AST), Creatinine(Cr), Creatine kinase (CK)were monitored and compared before treatment and after treatment of 6,12 months. After 6months and 12months treatment the pitavastatin calcium group HDL-C were significantly elevated (P<0.05), hsCRP were significantly lower(P<0.05). After 6months and 12months the atorvastatin calcium group HDL-C and hsCRP compared to before treatment the difference were not statistically(P>0.05). The atorvastatin calcium group HbA1c were elevated after 12months treatment with statistically differences(P<0.05), but the pitavastatin calcium were not elevated(P>0.05). The two groups TC, LDL-C were lower with statistically significant differences(P<0.05). The differences between Glu, ALT, AST, Cr, CK before treatment and after treatment were without statistically differences (P>0.05), 1patient was removed because of transaminase elevated. Both pitavastatin calcium and atorvastatincalcium can lower LDL-C, TC、TG in Coronary Heart Disease patients, Moreover, the pitavastatin calcium can elevate HDL-C level and lower hsCRP level. Meanwhile, the pitavastatin calcium had no evidence in new diabetes, it was efficacy and safety in long-term treatment. [ABSTRACT FROM AUTHOR]